NCT05471674已完成2 期
Neoadjuvant Immunotherapy With Anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
Dr Tan-to CHEUNG1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2020年7月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Pathological tumour response rate
研究概览
简要总结
This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent form prior to the screening procedures.
- •Age ≥ 18 years.
- •Histological proof of HCC.
- •Willingness to undergo a pre-dosing fresh tumour biopsy. Patients for whom fresh biopsy may not be feasible will be ineligible for enrollment.
- •Intermediate or locally-advanced HCC (according to HKLC tumour status categorization) with the option of resection for potential cure as assessed by surgeon.
- •Child-Pugh score ≤ 7 with no symptomatic ascites or ascites requiring therapeutic paracentesis.
- •ECOG performance status ≤
- •Life expectancy of ≥ 12 weeks.
- •Adequate organ function (blood transfusion or use of biologic response modifiers is not permitted).
- •Measurable disease according to RECIST v1.
- •Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception.
- •Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception.
- •Able and willing to meet all protocol-required treatments, investigations and visits.
排除标准
- •Patients who have history of organ transplantation.
- •History of allergy or hypersensitivity to study drug components.
- •Patients who have active, known or suspected autoimmune disease. Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition adequately treated with hormonal replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger or deemed by the investigator not to affect safety assessment.
- •Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- •Patients who have received prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-regulatory pathways).
- •Receipt of any cancer therapy in the pre-operative period.
- •Treatment with botanical preparations (e.g., herbal supplements or traditional Chinese medicine) intended for general health support or to treat the disease under study within 2 weeks prior to treatment.
- •Active, acute, or chronic clinically significant infections requiring therapy with the exception of hepatitis B or C virus infection. Patients with chronic HBV infection must be on antiviral therapy and have HBV DNA < 500 IU/ml. Active or chronic co-infection with hepatitis B and C, or hepatitis B and D is not allowed.
- •Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •Symptomatic congestive heart failure, defined as ≥ Class II of the New York Heart Association functional classification system or known LVEF < 50% at baseline.
- •Active angina pectoris or recent myocardial infarction (within 6 months).
- •Chronic atrial fibrillation or QTcF > 470 msec.
- •History of other previous cancer that would interfere with the determination of safety or efficacy of nivolumab with respect to HCC.
- •Women who are pregnant or breast-feeding.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.
研究组 & 干预措施
Treatment
Experimental
干预措施: Nivolumab (Drug)
Treatment
Experimental
干预措施: Hepatectomy (Procedure)
结局指标
主要结局
Pathological tumour response rate
时间窗: After surgery (normally 6 weeks after the start of nivolumab)
Proportion of patients with resected tumours having ≥30% necrosis
次要结局
- Recurrence-free survival(At least 3 months after surgery)
- Overall survival(At least 3 months after surgery)
- Short-term surgery outcomes(2 weeks after surgery)
- Safety and tolerability of nivolumab(6 months)
研究者
Dr Tan-to CHEUNG
Clinical Associate Professor
The University of Hong Kong
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial TumorThymic Epithelial TumorNCT04667793Shanghai Pulmonary Hospital, Shanghai, China15
进行中（未招募）
2 期
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)Squamous Cell CarcinomaNCT04808999Diwakar Davar30
已完成
2 期
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)NCT03197467AIO-Studien-gGmbH30
招募中
2 期
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal CancerEarly Low Rectal CancerNCT05555888Fudan University34
招募中
2 期
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian CancerNeoadjuvant ChemotherapyAnti-PD-1Neoadjuvant ImmunotherapyOvarian CancerNCT04815408Second Affiliated Hospital, School of Medicine, Zhejiang University40